The Health Service Executive approved the reimbursement of the drug, Skyclarys, onTuesday 26 August 2026. This represents a reversal of the HSE Drugs Group initialrecommendation on 14 August, against the drug’s reimbursement. Skyclarys is the first drug available for the treatment of Friedreich’s Ataxia - a raregenetic condition which causes progressive damage to the nervous … [Read more...] about HSE decision reversal on potentially life-preserving drug